National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2023 (No. 8) (Cth)
PB 79 of 2023
National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2023
(No. 8)
National Health Act 1953
I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.
Dated 30 August 2023
NIKOLAI TSYGANOV
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Contents
1......... Name............................................................................................................................... 1
2......... Commencement............................................................................................................... 1
3......... Authority......................................................................................................................... 1
4......... Schedules......................................................................................................................... 1
Schedule 1—Amendments 2
National Health (Listing of Pharmaceutical Benefits) Instrument 2012
(PB 71 of 2012). 2
Name
(1)This instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2023 (No. 8).
(2)This Instrument may also be cited as PB 79 of 2023.
Commencement
(1)Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
| Commencement information | ||
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | Immediately after the commencement of Schedule 2 of the National Health Legislation Amendment (Opioid Dependence Treatment and Maximum Dispensed Quantities) Instrument 2023 (PB 57 of 2023). | |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2)Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
Authority
This instrument is made under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.
4 Schedules
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)
Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 1; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14133
(b)insert in numerical order in the column headed “Circumstances”: C14275
Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 1; Number of Repeats: 3]
(a)omit from the column headed “Circumstances” (all instances): C14133
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14275
Schedule 1, Part 1, entry for Adapalene with benzoyl peroxide in the form Gel 1 mg-25 mg per g, 30 g [Maximum Quantity: 2; Number of Repeats: 3]
(a)omit from the column headed “Circumstances” (all instances): C14133
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14275
(c)omit from the column headed “Purposes” (all instances): P14133 substitute (all instances): P14275
Schedule 1, Part 1, entry for Alendronic acid in the form Tablet 70 mg (as alendronate sodium) [Maximum Quantity: 4; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14242 C14291 C14309
Schedule 1, Part 1, entry for Alendronic acid in the form Tablet 70 mg (as alendronate sodium) [Maximum Quantity: 8; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14027 C14028 C14089
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14242 C14291 C14309
(c)omit from the column headed “Purposes” (all instances): P14027 P14028 P14089 substitute (all instances): P14242 P14291 P14309
Schedule 1, Part 1, entry for Allopurinol in the form Tablet 100 mg [Maximum Quantity: 400; Number of Repeats: 2]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Allopurinol in the form Tablet 300 mg [Maximum Quantity: 120; Number of Repeats: 2]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine in the form Tablet 5 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine in the form Tablet 10 mg (as besilate) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 5 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 10 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 20 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 40 mg atorvastatin (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Amlodipine with atorvastatin in the form Tablet 10 mg amlodipine (as besilate) with 80 mg atorvastatin (as calcium)
omit:
| a | Cadivast 10/80 | AF | MP NP | P14141 | 60 | 5 | 30 |
| a | Caduet 10/80 | AS | MP NP | P14141 | 60 | 5 | 30 |
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-80 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-80 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c)omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-160 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-160 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c)omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-320 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 5 mg (as besilate)-320 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c)omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-160 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-160 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c)omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-320 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
Schedule 1, Part 1, entry for Amlodipine with valsartan in the form Tablet 10 mg (as besilate)-320 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14043
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14257
(c)omit from the column headed “Purposes” (all instances): P14043 substitute (all instances): P14257
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c)omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 5 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c)omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-12.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c)omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-160 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c)omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
Schedule 1, Part 1, entry for Amlodipine with valsartan and hydrochlorothiazide in the form Tablet 10 mg (as besilate)-320 mg-25 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14062
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14272
(c)omit from the column headed “Purposes” (all instances): P14062 substitute (all instances): P14272
Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 20; Number of Repeats: 0]
(a)omit from the column headed “Circumstances”: C14078 C14139
(b)insert in numerical order in the column headed “Circumstances”: C14300 C14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 30; Number of Repeats: 0]
(a)omit from the column headed “Circumstances”: C14078 C14139
(b)insert in numerical order in the column headed “Circumstances”: C14300 C14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 0]
(a)omit from the column headed “Circumstances”: C14078 C14139
(b)insert in numerical order in the column headed “Circumstances”: C14300 C14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078 C14139
(b)insert in numerical order in the column headed “Circumstances”: C14300 C14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 2.5 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078 C14139
(b)insert in numerical order in the column headed “Circumstances”: C14300 C14308
(c)omit from the column headed “Purposes”: P14078 P14139 substitute: P14300 P14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 28; Number of Repeats: 0]
(a)omit from the column headed “Circumstances”: C14078 C14095 C14129
(b)insert in numerical order in the column headed “Circumstances”: C14264 C14302 C14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078 C14095 C14129
(b)insert in numerical order in the column headed “Circumstances”: C14264 C14302 C14308
Schedule 1, Part 1, entry for Apixaban in the form Tablet 5 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078 C14095 C14129
(b)insert in numerical order in the column headed “Circumstances”: C14264 C14302 C14308
(c)omit from the column headed “Purposes”: P14078 P14095 P14129 substitute: P14264 P14302 P14308
Schedule 1, Part 1, entry for Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL [Maximum Quantity: 1; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14039
(b)insert in numerical order in the column headed “Circumstances”: C14305
Schedule 1, Part 1, entry for Atenolol in the form Oral solution 50 mg in 10 mL, 300 mL [Maximum Quantity: 2; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14039
(b)insert in numerical order in the column headed “Circumstances”: C14305
(c)omit from the column headed “Purposes”: P14039 substitute: P14305
Schedule 1, Part 1, entry for Atenolol in the form Tablet 50 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 10 mg (as calcium)
omit:
| a | APO‑Atorvastatin | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 10 | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED ATORVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor Atorvastatin | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas | RA | MP | P7598 | 30 | 11 | 30 |
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 10 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium)
omit:
| a | APO‑Atorvastatin | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 20 | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED ATORVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor Atorvastatin | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas | RA | MP | P7598 | 30 | 11 | 30 |
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 20 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 40 mg (as calcium)
omit:
| a | APO‑Atorvastatin | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 40 | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED ATORVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor Atorvastatin | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas | RA | MP | P7598 | 30 | 11 | 30 |
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 40 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium)
omit:
| a | APO‑Atorvastatin | TX | MP | P7598 | 30 | 11 | 30 |
| a | Atorvachol | RF | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin GH | GQ | MP | P7598 | 30 | 11 | 30 |
| a | Atorvastatin SZ | HX | MP | P7598 | 30 | 11 | 30 |
| a | Blooms the Chemist Atorvastatin | IB | MP | P7598 | 30 | 11 | 30 |
| a | Lipitor | AS | MP | P7598 | 30 | 11 | 30 |
| a | Lorstat 80 | AF | MP | P7598 | 30 | 11 | 30 |
| a | NOUMED ATORVASTATIN | VO | MP | P7598 | 30 | 11 | 30 |
| a | Pharmacor Atorvastatin | CR | MP | P7598 | 30 | 11 | 30 |
| a | Trovas | RA | MP | P7598 | 30 | 11 | 30 |
Schedule 1, Part 1, entry for Atorvastatin in the form Tablet 80 mg (as calcium) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Baclofen in the form Tablet 10 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Baclofen in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Balsalazide in the form Capsule containing balsalazide sodium 750 mg [Maximum Quantity: 280; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14084
(b)insert in numerical order in the column headed “Circumstances”: C14306
Schedule 1, Part 1, entry for Balsalazide in the form Capsule containing balsalazide sodium 750 mg [Maximum Quantity: 560; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14084
(b)insert in numerical order in the column headed “Circumstances”: C14306
(c)omit from the column headed “Purposes”: P14084 substitute: P14306
Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 2.5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c)omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 5 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c)omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
Schedule 1, Part 1, entry for Bisoprolol in the form Tablet containing bisoprolol fumarate 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c)omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Maximum Quantity: 1; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14091
(b)insert in numerical order in the column headed “Circumstances”: C14236
Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g [Maximum Quantity: 2; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14091
(b)insert in numerical order in the column headed “Circumstances”: C14236
(c)omit from the column headed “Purposes”: P14091 substitute: P14236
Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g [Maximum Quantity: 1; Number of Repeats: 1]
(a)omit from the column headed “Circumstances” (all instances): C14091
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14236
Schedule 1, Part 1, entry for Calcipotriol with betamethasone in the form Ointment containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 30 g [Maximum Quantity: 2; Number of Repeats: 1]
(a)omit from the column headed “Circumstances” (all instances): C14091
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14236
(c)omit from the column headed “Purposes” (all instances): P14091 substitute (all instances): P14236
Schedule 1, Part 1, entry for Calcitriol in the form Capsule 0.25 microgram [Maximum Quantity: 100; Number of Repeats: 3]
(a)omit from the column headed “Circumstances” (all instances): C14071 C14087 C14088 C14100 C14111
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14231 C14259 C14287 C14296 C14322
Schedule 1, Part 1, entry for Calcitriol in the form Capsule 0.25 microgram [Maximum Quantity: 200; Number of Repeats: 3]
(a)omit from the column headed “Circumstances” (all instances): C14071 C14087 C14088 C14100 C14111
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14231 C14259 C14287 C14296 C14322
(c)omit from the column headed “Purposes” (all instances): P14071 P14087 P14088 P14100 P14111 substitute (all instances): P14231 P14259 P14287 P14296 P14322
Schedule 1, Part 1, entry for Calcium in the form Tablet, chewable, 500 mg (as carbonate) [Maximum Quantity: 240; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14054
(b)insert in numerical order in the column headed “Circumstances”: C14228
Schedule 1, Part 1, entry for Calcium in the form Tablet, chewable, 500 mg (as carbonate) [Maximum Quantity: 480; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14054
(b)insert in numerical order in the column headed “Circumstances”: C14228
(c)omit from the column headed “Purposes”: P14054 substitute: P14228
Schedule 1, Part 1, entry for Calcium in the form Tablet 600 mg (as carbonate) [Maximum Quantity: 240; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14054
(b)insert in numerical order in the column headed “Circumstances”: C14228
Schedule 1, Part 1, entry for Calcium in the form Tablet 600 mg (as carbonate) [Maximum Quantity: 480; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14054
(b)insert in numerical order in the column headed “Circumstances”: C14228
(c)omit from the column headed “Purposes”: P14054 substitute: P14228
Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 4 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 8 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 16 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Candesartan in the form Tablet containing candesartan cilexetil 32 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c)omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c)omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
Schedule 1, Part 1, entry for Candesartan with hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c)omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
Schedule 1, Part 1, entry for Carvedilol in the form Tablet 6.25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033 C14115
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
Schedule 1, Part 1, entry for Carvedilol in the form Tablet 6.25 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033 C14115
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
(c)omit from the column headed “Purposes” (all instances): P14033 P14115 substitute (all instances): P14251 P14270
Schedule 1, Part 1, entry for Carvedilol in the form Tablet 12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033 C14115
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
Schedule 1, Part 1, entry for Carvedilol in the form Tablet 12.5 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033 C14115
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
(c)omit from the column headed “Purposes” (all instances): P14033 P14115 substitute (all instances): P14251 P14270
Schedule 1, Part 1, entry for Carvedilol in the form Tablet 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033 C14115
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
Schedule 1, Part 1, entry for Carvedilol in the form Tablet 25 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033 C14115
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251 C14270
(c)omit from the column headed “Purposes” (all instances): P14033 P14115 substitute (all instances): P14251 P14270
Schedule 1, Part 1, entry for Chlortalidone in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Clonidine in the form Tablet containing clonidine hydrochloride 100 micrograms [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
(b)insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
| a | Clonidine Lupin | GQ | MP NP | P14238 | 200 | 5 | 100 |
Schedule 1, Part 1, entry for Clonidine in the form Tablet containing clonidine hydrochloride 150 micrograms [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Clopidogrel in the form Tablet 75 mg (as besilate) [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Clopidogrel in the form Tablet 75 mg (as hydrogen sulfate) [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Clopidogrel with aspirin in the form Tablet 75 mg (as hydrogen sulfate)-100 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 20; Number of Repeats: 0]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 20; Number of Repeats: 1]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 0]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 110 mg (as mesilate) [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
(c)omit from the column headed “Purposes”: P14078 substitute: P14308
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
Schedule 1, Part 1, entry for Dabigatran etexilate in the form Capsule 150 mg (as mesilate) [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14078
(b)insert in numerical order in the column headed “Circumstances”: C14308
(c)omit from the column headed “Purposes”: P14078 substitute: P14308
Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Enalapril in the form Tablet containing enalapril maleate 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Enalapril with hydrochlorothiazide in the form Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14107
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14280
Schedule 1, Part 1, entry for Enalapril with hydrochlorothiazide in the form Tablet containing enalapril maleate 20 mg with hydrochlorothiazide 6 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14107
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14280
(c)omit from the column headed “Purposes” (all instances): P14107 substitute (all instances): P14280
Schedule 1, Part 1, entry for Eplerenone in the form Tablet 25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14035
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14266
Schedule 1, Part 1, entry for Eplerenone in the form Tablet 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14035
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14266
(c)omit from the column headed “Purposes” (all instances): P14035 substitute (all instances): P14266
Schedule 1, Part 1, entry for Eplerenone in the form Tablet 50 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14035
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14266
Schedule 1, Part 1, entry for Eplerenone in the form Tablet 50 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14035
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14266
(c)omit from the column headed “Purposes” (all instances): P14035 substitute (all instances): P14266
Schedule 1, Part 1, entry for Ezetimibe in the form Tablet 10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14135 C14136 C14137
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14249 C14283 C14310
Schedule 1, Part 1, entry for Ezetimibe in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14135 C14136 C14137
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14249 C14283 C14310
(c)omit from the column headed “Purposes” (all instances): P14135 P14136 P14137 substitute (all instances): P14249 P14283 P14310
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a)insert in numerical order in the column headed “Circumstances” (all instances): C14350
(b)insert in the column headed “Purposes” (all instances): P7958
Schedule 1, Part 1, after entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 5 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
insert:
| a | Ezalo Composite Pack 10mg+5mg | AF | MP NP | C7958 C14350 | P14350 | 2 | 5 | 1 |
| a | Rosuzet Composite Pack | AL | MP NP | C7958 C14350 | P14350 | 2 | 5 | 1 |
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 10 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 20 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) [Maximum Quantity: 1; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe and rosuvastatin in the form Pack containing 30 tablets ezetimibe 10 mg and 30 tablets rosuvastatin 40 mg (as calcium) [Maximum Quantity: 2; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14056
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14269
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14056
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14269
(c)omit from the column headed “Purposes” (all instances): P14056 substitute (all instances): P14269
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)insert in numerical order in the column headed “Circumstances” (all instances): C14348
(b)insert in the column headed “Purposes” (all instances): P7957
Schedule 1, Part 1, after entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]
insert:
| a | Atozet | AF | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 |
| a | Ezetast | XT | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 |
| a | Ezetimibe/Atorvastatin GH 10/20 | GQ | MP NP | C7957 C14348 | P14348 | 60 | 5 | 30 |
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe with atorvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14056
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14269
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-10 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14056
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14269
(c)omit from the column headed “Purposes” (all instances): P14056 substitute (all instances): P14269
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14056
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14269
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-20 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14056
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14269
(c)omit from the column headed “Purposes” (all instances): P14056 substitute (all instances): P14269
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-40 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
Schedule 1, Part 1, entry for Ezetimibe with simvastatin in the form Tablet 10 mg-80 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14057
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14284
(c)omit from the column headed “Purposes” (all instances): P14057 substitute (all instances): P14284
Schedule 1, Part 1, entry for Febuxostat in the form Tablet 80 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14121
(b)insert in numerical order in the column headed “Circumstances”: C14313
Schedule 1, Part 1, entry for Febuxostat in the form Tablet 80 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14121
(b)insert in numerical order in the column headed “Circumstances”: C14313
(c)omit from the column headed “Purposes”: P14121 substitute: P14313
Schedule 1, Part 1, entry for Felodipine in the form Tablet 2.5 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Purposes” (all instances): P14141
(b)insert in numerical order in the column headed “Purposes” (all instances): P14238
Schedule 1, Part 1, entry for Felodipine in the form Tablet 5 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Purposes” (all instances): P14141
(b)insert in numerical order in the column headed “Purposes” (all instances): P14238
Schedule 1, Part 1, entry for Felodipine in the form Tablet 10 mg (extended release) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Purposes” (all instances): P14141
(b)insert in numerical order in the column headed “Purposes” (all instances): P14238
Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 48 mg
omit:
| a | APO‑Fenofibrate | TX | MP | P7640 | 60 | 11 | 60 |
| a | Fenofibrate Cipla | LR | MP | P7640 | 60 | 11 | 60 |
| a | Fenofibrate Mylan | AF | MP | P7640 | 60 | 11 | 60 |
| a | FENOFIBRATE RBX | RA | MP | P7640 | 60 | 11 | 60 |
| a | Fenofibrate Viatris | AL | MP | P7640 | 60 | 11 | 60 |
| a | Lipidil | GO | MP | P7640 | 60 | 11 | 60 |
Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 48 mg [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit:
| a | Fenofibrate Mylan | AF | MP | P14141 | 120 | 5 | 60 |
(b)omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 145 mg
omit:
| a | APO‑Fenofibrate | TX | MP | P7640 | 30 | 11 | 30 |
| a | Blooms the Chemist Fenofibrate | IB | MP | P7640 | 30 | 11 | 30 |
| a | Fenocol | YC | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Cipla | LR | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Mylan | AF | MP | P7640 | 30 | 11 | 30 |
| a | FENOFIBRATE RBX | RA | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Sandoz | SZ | MP | P7640 | 30 | 11 | 30 |
| a | Fenofibrate Viatris | AL | MP | P7640 | 30 | 11 | 30 |
| a | Lipidil | GO | MP | P7640 | 30 | 11 | 30 |
Schedule 1, Part 1, entry for Fenofibrate in the form Tablet 145 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit:
| a | Fenofibrate Mylan | AF | MP | P14141 | 60 | 5 | 30 |
(b)omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Fluvastatin
omit:
| MP | P7598 | 28 | 11 | 28 |
Schedule 1, Part 1, entry for Fluvastatin in the form Tablet (prolonged release) 80 mg (as sodium) [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Furosemide in the form Oral solution 10 mg per mL, 30 mL [Maximum Quantity: 2; Number of Repeats: 3]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Furosemide in the form Tablet 20 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Furosemide in the form Tablet 40 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Furosemide in the form Tablet 500 mg [Maximum Quantity: 100; Number of Repeats: 3]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Gemfibrozil
omit:
| a | Ausgem | RW | MP | P7640 | 60 | 11 | 60 |
| a | Lipigem | AF | MP | P7640 | 60 | 11 | 60 |
Schedule 1, Part 1, after entry for Gemfibrozil in the form Tablet 600 mg
insert:
| a | Ausgem | RW | MP NP | P14238 | 120 | 5 | 60 |
| a | Lipigem | AF | MP NP | P14238 | 120 | 5 | 60 |
Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Transdermal patch 25 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Transdermal patch 50 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Glyceryl trinitrate in the form Sublingual spray (pump pack) 400 micrograms per dose, 200 doses [Maximum Quantity: 2; Number of Repeats: 5]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Hydralazine in each of the forms: Tablet containing hydralazine hydrochloride 25 mg; and Tablet containing hydralazine hydrochloride 50 mg
omit:
| MP NP | P14141 | 400 | 2 | 100 |
Schedule 1, Part 1, entry for Hydrochlorothiazide in the form Tablet 25 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Hydrochlorothiazide with amiloride in the form Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg [Maximum Quantity: 200; Number of Repeats: 1]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Indapamide in the form Tablet containing indapamide hemihydrate 1.5 mg (sustained release) [Maximum Quantity: 180; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Indapamide in the form Tablet containing indapamide hemihydrate 2.5 mg [Maximum Quantity: 180; Number of Repeats: 1]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Irbesartan in the form Tablet 75 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Irbesartan in the form Tablet 150 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Irbesartan in the form Tablet 300 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 150 mg-12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c)omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-12.5 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c)omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
Schedule 1, Part 1, entry for Irbesartan with hydrochlorothiazide in the form Tablet 300 mg-25 mg [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14061
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14255
(c)omit from the column headed “Purposes” (all instances): P14061 substitute (all instances): P14255
Schedule 1, Part 1, entry for Isosorbide dinitrate in the form Tablet 5 mg (sublingual) [Maximum Quantity: 400; Number of Repeats: 2]
omit from the column headed “Purposes”: P14141 substitute: P14238
Schedule 1, Part 1, entry for Isosorbide mononitrate in the form Tablet 60 mg (sustained release) [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, after entry for Isosorbide mononitrate in the form Tablet 120 mg (sustained release)
insert:
| a | Imdur 120 mg | IX | MP NP | P14238 | 60 | 5 | 30 |
| a | Monodur 120 mg | IY | MP NP | P14238 | 60 | 5 | 30 |
Schedule 1, Part 1, entry for Labetalol
omit:
| MP NP | P14141 | 200 | 5 | 100 |
Schedule 1, Part 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Lercanidipine in the form Tablet containing lercanidipine hydrochloride 20 mg [Maximum Quantity: 56; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14049
(b)insert in numerical order in the column headed “Circumstances”: C14245
Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 10 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14049
(b)insert in numerical order in the column headed “Circumstances”: C14245
(c)omit from the column headed “Purposes”: P14049 substitute: P14245
Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg [Maximum Quantity: 28; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14049
(b)insert in numerical order in the column headed “Circumstances”: C14245
Schedule 1, Part 1, entry for Lercanidipine with enalapril in the form Tablet containing lercanidipine hydrochloride 10 mg with enalapril maleate 20 mg [Maximum Quantity: 56; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14049
(b)insert in numerical order in the column headed “Circumstances”: C14245
(c)omit from the column headed “Purposes”: P14049 substitute: P14245
Schedule 1, Part 1, entry for Lisinopril in the form Tablet 5 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Lisinopril in the form Tablet 10 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Lisinopril in the form Tablet 20 mg [Maximum Quantity: 60; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 500 mg per sachet [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 500 mg per sachet [Maximum Quantity: 400; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1 g per sachet [Maximum Quantity: 100; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1 g per sachet [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet [Maximum Quantity: 100; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 1 g per sachet [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1.5 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 1.5 g per sachet [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 2 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 2 g per sachet [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 3 g per sachet [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing granules, 3 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 250 mg (enteric coated) [Maximum Quantity: 100; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 250 mg (enteric coated) [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (enteric coated) [Maximum Quantity: 400; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (prolonged release) [Maximum Quantity: 200; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 500 mg (prolonged release) [Maximum Quantity: 400; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated) [Maximum Quantity: 90; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 800 mg (enteric coated) [Maximum Quantity: 180; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (enteric coated) [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (enteric coated) [Maximum Quantity: 240; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (prolonged release) [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1 g (prolonged release) [Maximum Quantity: 240; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14023 C14024
(b)insert in numerical order in the column headed “Circumstances”: C14229 C14260
(c)omit from the column headed “Purposes”: P14023 P14024 substitute: P14229 P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.2 g (prolonged release) [Maximum Quantity: 120; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14023
(b)insert in numerical order in the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14260
(c)omit from the column headed “Circumstances” for the brand “MESALZ”: C14120
(d)insert in numerical order in the column headed “Circumstances” for the brand “MESALZ”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.2 g (prolonged release) [Maximum Quantity: 240; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14023
(b)insert in numerical order in the column headed “Circumstances” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: C14260
(c)omit from the column headed “Circumstances” for the brand “MESALZ”: C14120
(d)insert in numerical order in the column headed “Circumstances” for the brand “MESALZ”: C14260
(e)omit from the column headed “Purposes” for the brands “Mesalazine 1.2 TAKEDA” and “Mezavant”: P14023 substitute: P14260
(f)omit from the column headed “Purposes” for the brand “MESALZ”: P14120 substitute: P14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.6 g (enteric coated) [Maximum Quantity: 120; Number of Repeats: 4]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
Schedule 1, Part 1, entry for Mesalazine in the form Tablet 1.6 g (enteric coated) [Maximum Quantity: 240; Number of Repeats: 4]
(a)omit from the column headed “Circumstances”: C14023
(b)insert in numerical order in the column headed “Circumstances”: C14260
(c)omit from the column headed “Purposes”: P14023 substitute: P14260
Schedule 1, Part 1, entry for Methyldopa in the form Tablet 250 mg (as sesquihydrate) [Maximum Quantity: 100; Number of Repeats: 5]
(a)omit from the column headed “Circumstances”: C14141
(b)omit from the column headed “Purposes”: P13887
Schedule 1, Part 1, entry for Methyldopa
omit:
| MP NP | C13887 C14141 | P14141 | 200 | 5 | 100 |
Schedule 1, Part 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 50 mg [Maximum Quantity: 200; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Metoprolol in the form Tablet containing metoprolol tartrate 100 mg [Maximum Quantity: 120; Number of Repeats: 5]
omit from the column headed “Purposes” (all instances): P14141 substitute (all instances): P14238
Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 47.5 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 47.5 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
(c)omit from the column headed “Purposes” (all instances): P14033 substitute (all instances): P14251
Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 95 mg (controlled release) [Maximum Quantity: 30; Number of Repeats: 5]
(a)omit from the column headed “Circumstances” (all instances): C14033
(b)insert in numerical order in the column headed “Circumstances” (all instances): C14251
Schedule 1, Part 1, entry for Metoprolol succinate in the form Tablet 95 mg (controlled release) [Maximum Quantity: 60; Number of Repeats: 5]
Schedule 4, Part 1, entry for Ezetimibe with simvastatin [Circumstances Code: C14056]
(a)omit from the column headed “Circumstances Code”: C14056 substitute: C14269
(b)omit from the column headed “Purposes Code”: P14056substitute: P14269
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14056 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14269
Schedule 4, Part 1, entry for Ezetimibe with simvastatin [Circumstances Code: C14057]
(a)omit from the column headed “Circumstances Code”: C14057 substitute: C14284
(b)omit from the column headed “Purposes Code”: P14057substitute: P14284
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14057 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14284
Schedule 4, Part 1, entry for Febuxostat [Circumstances Code: C14121]
(a)omit from the column headed “Circumstances Code”: C14121 substitute: C14313
(b)omit from the column headed “Purposes Code”: P14121substitute: P14313
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14121 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14313
Schedule 4, Part 1, entry for Felodipine
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Fenofibrate [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Fluvastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Furosemide
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Gemfibrozil
insert in numerical order after existing text:
| P14238 | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
Schedule 4, Part 1, entry for Glyceryl trinitrate
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, omit entry for Hydralazine
Schedule 4, Part 1, entry for Hydrochlorothiazide
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Hydrochlorothiazide with amiloride
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Indapamide
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Irbesartan
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Irbesartan with hydrochlorothiazide [Circumstances Code: C14061]
(a)omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b)omit from the column headed “Purposes Code”: P14061substitute: P14255
Schedule 4, Part 1, entry for Isosorbide dinitrate
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Isosorbide mononitrate
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, omit entry for Labetalol
Schedule 4, Part 1, entry for Lercanidipine
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Lercanidipine with enalapril [Circumstances Code: C14049]
(a)omit from the column headed “Circumstances Code”: C14049 substitute: C14245
(b)omit from the column headed “Purposes Code”: P14049substitute: P14245
Schedule 4, Part 1, entry for Lisinopril
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Mesalazine
omit:
| C14023 | P14023 | Ulcerative colitis The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
Schedule 4, Part 1, entry for Mesalazine [Circumstances Code: C14024]
(a)omit from the column headed “Circumstances Code”: C14024 substitute: C14229
(b)omit from the column headed “Purposes Code”: P14024substitute: P14229
Schedule 4, Part 1, entry for Mesalazine [Circumstances Code: C14120]
(a)omit from the column headed “Circumstances Code”: C14120 substitute: C14260
(b)omit from the column headed “Purposes Code”: P14120substitute: P14260
Schedule 4, Part 1, entry for Methyldopa
(a)omit from the column headed “Purposes Code” for the Circumstances Code “C13887”: P13887
(b)omit:
| C14141 | P14141 | The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. |
Schedule 4, Part 1, entry for Metoprolol
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Metoprolol succinate [Circumstances Code: C14033]
(a)omit from the column headed “Circumstances Code”: C14033 substitute: C14251
(b)omit from the column headed “Purposes Code”: P14033substitute: P14251
Schedule 4, Part 1, entry for Moxonidine [Circumstances Code: C14037]
(a)omit from the column headed “Circumstances Code”: C14037 substitute: C14289
(b)omit from the column headed “Purposes Code”: P14037substitute: P14289
Schedule 4, Part 1, entry for Nebivolol [Circumstances Code: C14033]
(a)omit from the column headed “Circumstances Code”: C14033 substitute: C14251
(b)omit from the column headed “Purposes Code”: P14033substitute: P14251
Schedule 4, Part 1, entry for Nicorandil
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Nifedipine
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Olmesartan
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Olmesartan with amlodipine [Circumstances Code: C14043]
(a)omit from the column headed “Circumstances Code”: C14043 substitute: C14257
(b)omit from the column headed “Purposes Code”: P14043substitute: P14257
Schedule 4, Part 1, entry for Olmesartan with amlodipine and hydrochlorothiazide [Circumstances Code: C14062]
(a)omit from the column headed “Circumstances Code”: C14062 substitute: C14272
(b)omit from the column headed “Purposes Code”: P14062substitute: P14272
Schedule 4, Part 1, entry for Olmesartan with hydrochlorothiazide [Circumstances Code: C14061]
(a)omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b)omit from the column headed “Purposes Code”: P14061substitute: P14255
Schedule 4, Part 1, entry for Pancreatic extract [Circumstances Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Penicillamine
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Perindopril
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Perindopril with amlodipine [Circumstances Code: C14049]
(a)omit from the column headed “Circumstances Code”: C14049 substitute: C14245
(b)omit from the column headed “Purposes Code”: P14049substitute: P14245
Schedule 4, Part 1, entry for Perindopril with amlodipine [Circumstances Code: C14068]
(a)omit from the column headed “Circumstances Code”: C14068 substitute: C14246
(b)omit from the column headed “Purposes Code”: P14068substitute: P14246
Schedule 4, Part 1, entry for Perindopril with indapamide [Circumstances Code: C14098]
(a)omit from the column headed “Circumstances Code”: C14098 substitute: C14267
(b)omit from the column headed “Purposes Code”: P14098substitute: P14267
Schedule 4, Part 1, entry for Perindopril with indapamide [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Potassium chloride
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Potassium chloride with potassium bicarbonate
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Pravastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Prazosin
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, omit entry for Probenecid
Schedule 4, Part 1, entry for Propranolol
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, omit entry for Quinapril
Schedule 4, Part 1, entry for Raloxifene [Circumstances Code: C14101]
(a)omit from the column headed “Circumstances Code”: C14101 substitute: C14274
(b)omit from the column headed “Purposes Code”: P14101substitute: P14274
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14101 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14274
Schedule 4, Part 1, entry for Ramipril
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Ramipril with felodipine [Circumstances Code: C14049]
(a)omit from the column headed “Circumstances Code”: C14049 substitute: C14245
(b)omit from the column headed “Purposes Code”: P14049substitute: P14245
Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14027]
(a)omit from the column headed “Circumstances Code”: C14027 substitute: C14263
(b)omit from the column headed “Purposes Code”: P14027substitute: P14263
Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14028]
(a)omit from the column headed “Circumstances Code”: C14028 substitute: C14235
(b)omit from the column headed “Purposes Code”: P14028substitute: P14235
Schedule 4, Part 1, entry for Risedronic acid [Circumstances Code: C14089]
(a)omit from the column headed “Circumstances Code”: C14089 substitute: C14234
(b)omit from the column headed “Purposes Code”: P14089substitute: P14234
Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14059]
(a)omit from the column headed “Circumstances Code”: C14059 substitute: C14301
(b)omit from the column headed “Purposes Code”: P14059substitute: P14301
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14059 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14301
Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14075]
(a)omit from the column headed “Circumstances Code”: C14075 substitute: C14298
(b)omit from the column headed “Purposes Code”: P14075substitute: P14298
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14075 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14298
Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14095]
(a)omit from the column headed “Circumstances Code”: C14095 substitute: C14264
(b)omit from the column headed “Purposes Code”: P14095substitute: P14264
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14095 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14264
Schedule 4, Part 1, entry for Rivaroxaban
omit:
| C14116 | P14116 | Chronic stable atherosclerotic disease Initial treatment The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND The treatment must be in combination with aspirin, but not with any other anti-platelet therapy; AND Patient must have a diagnosis of coronary artery disease in addition to at least one of the following risk factors: (i) diagnosed heart failure (left ventricular ejection fraction of at least 30% but less than 50%) (ii) diagnosed kidney disease classified by an eGFR in the range of 15-60 mL/min (iii) diabetes mellitus combined with at least one of the following: (a) age at least 60 years (b) concomitant microalbuminuria (c) Aboriginal/Torres Strait Islander descent; OR Patient must have a diagnosis of peripheral artery disease in addition to at least one of the following risk factors: (i) concomitant coronary artery disease (ii) diagnosed heart failure (left ventricular ejection fraction of at least 30% but less than 50%) (iii) diagnosed kidney disease classified by an eGFR in the range of 15-60 mL/min (iv) diabetes mellitus combined with at least one of the following: (a) age at least 60 years (b) concomitant microalbuminuria (c) Aboriginal/Torres Strait Islander descent; AND Patient must have at least one of the following if coronary artery disease is present: (i) a previous multi-vessel coronary revascularisation procedure (ii) significant stenosis in at least 2 coronary arteries (iii) a previous single vessel coronary revascularisation procedure with significant stenosis in more than 1 coronary artery; OR Patient must have at least one of the following if peripheral arterial disease is present: (i) a previous peripheral/carotid artery revascularisation intervention (ii) intermittent claudication with an ankle-brachial index less than 0.9 (iii) asymptomatic carotid artery stenosis greater than 50%; AND The condition must be diagnosed by at least one of: (i) invasive (selective) angiography (ii) non-invasive imaging (i.e. CT scan, ultrasound) (iii) ankle-brachial index measurement in the case of peripheral arterial disease with intermittent claudication; AND Patient must have clinical findings/observations by the treating physician that exclude each of the following: (i) high risk of bleeding (ii) prior stroke within one month of treatment initiation (iii) prior haemorrhagic / lacunar stroke (iv) severe heart failure with a known ejection fraction less than 30% (v) New York Heart Association class III to IV heart failure symptoms (i.e. symptoms corresponding to moderate to severe limitation on physical activity, whereby any of fatigue/palpitations/dyspnoea occur upon zero to minimal activity) (vi) an estimated glomerular filtration rate less than 15 mL/minute (vii) a requirement for dual antiplatelet therapy (viii) a requirement for non-acetylsalicylic acid antiplatelet therapy (ix) a requirement for a higher dose of oral anticoagulant therapy. Must be treated by a specialist physician; OR Must be treated by a physician who has consulted a specialist physician. | Compliance with Authority Required procedures - Streamlined Authority Code 14116 |
Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14139]
(a)omit from the column headed “Circumstances Code”: C14139 substitute: C14300
(b)omit from the column headed “Purposes Code”: P14139substitute: P14300
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14139 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14300
Schedule 4, Part 1, entry for Rivaroxaban [Circumstances Code: C14140]
(a)omit from the column headed “Circumstances Code”: C14140 substitute: C14318
(b)omit from the column headed “Purposes Code”: P14140substitute: P14318
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14140 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14318
Schedule 4, Part 1, entry for Rosuvastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Sacubitril with valsartan [Circumstances Code: C14051]
(a)omit from the column headed “Circumstances Code”: C14051 substitute: C14254
(b)omit from the column headed “Purposes Code”: P14051substitute: P14254
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14051 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14254
Schedule 4, Part 1, entry for Simvastatin [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Spironolactone
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Sulfasalazine [Purposes Code: C14141]
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Telmisartan
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Telmisartan with amlodipine [Circumstances Code: C14043]
(a)omit from the column headed “Circumstances Code”: C14043 substitute: C14257
(b)omit from the column headed “Purposes Code”: P14043substitute: P14257
Schedule 4, Part 1, entry for Telmisartan with hydrochlorothiazide [Circumstances Code: C14061]
(a)omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b)omit from the column headed “Purposes Code”: P14061substitute: P14255
Schedule 4, Part 1, entry for Thiamine [Circumstances Code: C14020]
(a)omit from the column headed “Circumstances Code”: C14020 substitute: C14319
(b)omit from the column headed “Purposes Code”: P14020substitute: P14319
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14020 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14319
Schedule 4, Part 1, entry for Ticagrelor [Circumstances Code: C14076]
(a)omit from the column headed “Circumstances Code”: C14076 substitute: C14240
(b)omit from the column headed “Purposes Code”: P14076substitute: P14240
(c)omit from the column headed “Authority Requirements (part of Circumstances; or Conditions)”: Compliance with Authority Required procedures - Streamlined Authority Code 14076 substitute: Compliance with Authority Required procedures - Streamlined Authority Code 14240
Schedule 4, Part 1, entry for Trandolapril
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Trandolapril with verapamil [Circumstances Code: C14119]
(a)omit from the column headed “Circumstances Code”: C14119 substitute: C14244
(b)omit from the column headed “Purposes Code”: P14119substitute: P14244
Schedule 4, Part 1, entry for Valsartan
omit from the column headed “Purposes Code”: P14141substitute: P14238
Schedule 4, Part 1, entry for Valsartan with hydrochlorothiazide [Circumstances Code: C14061]
(a)omit from the column headed “Circumstances Code”: C14061 substitute: C14255
(b)omit from the column headed “Purposes Code”: P14061substitute: P14255
Schedule 4, Part 1, entry for Valsartan with hydrochlorothiazide [Circumstances Code: C14108]
(a)omit from the column headed “Circumstances Code”: C14108 substitute: C14311
(b)omit from the column headed “Purposes Code”: P14108substitute: P14311
Schedule 4, Part 1, entry for Verapamil
omit from the column headed “Purposes Code”: P14141substitute: P14238
0
0
0